European Leukemia Trial Registry
Trial: RICMAC

More Details
Title Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML
Scientific Title Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study
Short Title RICMAC
Trialgroup EBMT
Type of Trial multicentric, randomized
Disease Stem cell transplantation(SCT) AML
Acute myeloid leukemia(AML) Stem cell transplantation
Stem cell transplantation(SCT) MDS
Myelodysplastic Syndrome(MDS) Stem cell transplantation
Age <= 55 years HLA - matched unrelated donor and age between 18 – 55 years
Status No longer recruiting
Start of Recruitment 01.05.2004
Leader Kröger, Prof. Dr. med., Nicolaus
Contactperson

Study Physician
van Os, Dr. med., Marleen
Tel: +31 (0)71 5269722
Email: clwpebmt@lumc.nl

Study Physician
van Biezen, Dr. med., Anja
Tel: +31 (0)71 5269722
Email: clwpebmt@lumc.nl

Centre of Trial Universitätsklinikum Hamburg-Eppendorf
Shortprotocol Shortprotocol
created 01.08.2006 Anja Hellenbrecht
changed 10.07.2013 Sina Hehn
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org